Research Progress of Targeted Drug Therapy and Tumor Microenvironment Therapy for Non-Small Cell Lung Cancer

Youlin Zheng

doi:10.54097/3ccrtk24

Authors

Youlin Zheng

DOI:

https://doi.org/10.54097/3ccrtk24

Keywords:

Non-Small Cell Lung Cancer (NSCLC), Immunotherapy, Targeted Drug Therapy, Tumor Microenvironment

Abstract

In the past few years, along with the advancement of tumor immunology, immunotherapeutic approaches have offered more potent therapeutic choices for individuals diagnosed with cancer. Based on traditional chemotherapy and radiotherapy, immunotherapy has offered patients more effective strategies and better prognosis. Among them, immune-targeted drug therapy and tumor microenvironment therapy have achieved remarkable results in the management of non-small cell lung cancer (NSCLC). This study will elaborate on the mechanisms, research status quo and developments of targeted drug therapy and tumor microenvironment therapy in managing NSCLC.

Downloads

Download data is not yet available.

References

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 74(3), 229–263.

[2] Ma J.X., Ma C.Q., Fan W.W., Zhao X.J., Peng X.X. (2024). Current Status and Progress of Targeted Therapy for Non-Small Cell Lung Cancer. Journal of Shandong Second Medical University, 46(06).

[3] Zhang, Q., Duan, J., Zhang, Y., Yang, L., & Li, D. (2025). Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis. Systematic reviews, 14(1), 24.

[4] Xu, P., & Li, H. (2017). Chinese journal of lung cancer, 20(4), 272–277.

[5] Chen, X. X., & Zhou, C. C. (2017). Chinese journal of oncology, 39(6), 401–404.

[6] Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018). Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of hematology & oncology, 11(1), 39.

[7] Li, Y., Li, C., Zhao, X., Li, Y., He, F., & Pan, Z. (2025). Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial. The oncologist, 30(3), oyae336.

[8] Awad, M. M., Gadgeel, S. M., Borghaei, H., Patnaik, A., Yang, J. C., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Altan, M., Jalal, S. I., Panwalkar, A., Gubens, M., Sequist, L. V., Saraf, S., Zhao, B., Piperdi, B., & Langer, C. J. (2021). Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer, 16(1), 162–168.

[9] Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., Wang, Q., Cheng, Y., Wu, F., Chen, J., Lin, X., Wang, Y., Huang, J., Cui, J., Cao, L., Liu, Y., … CameL Study Group (2021). Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Respiratory medicine, 9(3), 305–314.

[10] Yang GX, Cheng YT, Liu LL, Chen XY, Zhang XM. (2023). Clinical Study on Aumolertinib Tablets Combined with Bevacizumab Injection in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation. The Chinese Journal of Clinical Pharmacology, 39(11).

[11] Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S. W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O'Byrne, K. J., … Ramalingam, S. S. (2019). Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine, 381(21), 2020–2031.

[12] Zhou, C., Dong, X., Chen, G., Wang, Z., Wu, X., Yao, Y., Zhang, Y., Cheng, Y., Pan, H., Zhang, X., Cui, J., Wang, L., Chen, X., Li, X., Wang, Z., Wang, Q., He, J., Wang, M., Yan, I., Qian, L., … Srivastava, M. K. (2025). Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial. Nature medicine, 31(7), 2375–2384.

[13] Luo HM, Zou JF, Zhao JF, Sun CX, Yang JW. (2024). Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined with Bevacizumab in the Treatment of Advanced Non-Small Cell Lung Cancer. China Pharmacy, 35(23).

[14] Rahal, Z., El Darzi, R., Moghaddam, S. J., Cascone, T., & Kadara, H. (2025). Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nature reviews. Clinical oncology, 22(7), 463–482.

[15] Rajan, A., Abdul Sater, H., Rahma, O., Agajanian, R., Lassoued, W., Marté, J. L., Tsai, Y. T., Donahue, R. N., Lamping, E., Bailey, S., Weisman, A., Walter-Rodriguez, B., Ito, R., Vugmeyster, Y., Sato, M., Machl, A., Schlom, J., & Gulley, J. L. (2024). Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer, 12(3), e008480.

[16] Chen GR, Liu WY, Bao BH, Ye YC, Hu AY, Sun JZ. (2025). Mechanism of Transforming Growth Factor-β Affecting the Tumor Microenvironment of Non-Small Cell Lung Cancer and Its Intervention Potential. Journal of Cardiovascular and Pulmonary Diseases, 44 (2): 212-216.